Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. officially listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking a significant milestone in the company's development and its entry into the "H+A" dual capital operation model [2][4]. Group 1: Listing Details - The company issued shares at a price of 26.68 yuan per share, with an opening price of 58 yuan per share, reflecting a 117.4% increase. The stock price later surged over 160%, closing at 65.8 yuan per share, which represents a 146.63% increase, resulting in a total market capitalization of 29.406 billion yuan [2]. Group 2: Company Mission and Vision - The chairman of the company, Shen Yulei, emphasized the commitment to return value to investors and society through excellent operational performance. The company aims to become a global source of new drugs, driven by innovative technology in drug research and development [4][5]. Group 3: Business Operations - Baiaosaitu focuses on drug discovery based on mouse models and clinical pre-CRO services, as well as antibody drug development. The company has developed the RenMice® platform for discovering therapeutic monoclonal antibodies and has initiated a large-scale drug development plan targeting over 1,000 potential druggable targets [5][6]. Group 4: Partnerships and Collaborations - As of June 30, the company has signed approximately 280 drug cooperation development/authorization/transfer agreements and has established over 50 target project collaborations with multinational corporations using the RenMice® platform [6].